IP Library Granted Patent US 12,534,429
Granted Patent B2
US 12,534,429 · App. 17/982,182 · Granted Jan 27, 2026

Heterodimers of glutamic acid

Inventors: John W. Babich (Cambridge, MA); Craig N. Zimmerman (Cambridge, MA); Kevin P. Maresca (Cambridge, MA)
Assignee: Molecular Insight Pharmaceuticals, Inc.
C07C275/16A61K39/385C07B59/001C07C275/24C07C275/30C07C311/19C07D213/38
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,534,429
App. No.
17/982,182
Granted
Jan 27, 2026
Kind
B2
Abstract

Compounds of Formula (Ia) wherein R is a C 6 -C 12 substituted or unsubstituted aryl, a C 6 -C 12 substituted or unsubstituted heteroaryl, a C 1 -C 6 substituted or unsubstituted alkyl or —NR′R′, Q is C(O), O, NR′, S, S(O) 2 , C(O) 2 (CH2)p Y is C(O), O, NR′, S, S(O) 2 , C(O) 2 , (CH2)p Z is H or C 1 -C 4 alkyl, R′ is H, C(O), S(O) 2 , C(O) 2 , a C 6 -C 12 substituted or unsubstituted aryl, a C 6 -C 12 substituted or unsubstituted heteroaryl or a C 1 -C 6 substituted of unsubstituted when substituted, aryl, heteroaryl and alkyl are substituted with halogen, C 6 -C 12 heteroaryl, —NR′R′ or COOZ, which have diagnostic and therapeutic properties, such as the treatment and management of prostate cancer and other diseases related to NAALADase inhibition, Radiolabels can be incorporated into the structure through a variety of prosthetic, groups attached at the X amino acid side chain via a carbon or hetero atom linkage.

Claims (5)

1 . A compound comprising (i) a glutamate-urea-lysine moiety, (ii) a tether, and (iii) a metal chelating moiety comprising a radionuclide, or a pharmaceutically acceptable salt thereof, wherein the glutamate-urea-lysine moiety is of a structure:

and the tether is appended on one end to the glutamate-urea-lysine moiety at the position marked and on the other end to the metal chelating moiety.

2 . The compound of claim 1 , wherein the radionuclide is a therapeutic radionuclide.

3 . The compound of claim 1 , wherein the radionuclide is an imaging radionuclide.

4 . The compound of claim 3 , wherein the radionuclide is selected from technetium-99m, rhenium-186, rhenium-188, radio copper, and combinations thereof.

Assignments (1)
SECURITY INTEREST Recorded Dec 2, 2022
From: LANTHEUS MEDICAL IMAGING, INC.; MOLECULAR INSIGHT PHARMACEUTICALS, INC.; PSMA DEVELOPMENT COMPANY, LLC; PROGENICS PHARMACEUTICALS, INC.
To: CITIZENS BANK, N.A.
Reel/Frame 062047/0960 →